PixCell Medical Technologies Ltd. Announces $2 Million Raise Following Successful Completion of CE Mark Registration of the HemoScreen CBC Analyzer

Investment to expand clinical use of the innovative HemoScreen CBC Analyzer and Disposable Cartridges.

Yokneam Ilit, Israel, October 1st, 2013 (PRWEB) October 04, 2013 -- PixCell Medical Technologies Ltd. a privately held company focused on developing its patented Cell Based Diagnostics technology for the Point of Care (POC), announced that it has raised $2 million following successful completion of CE mark registration of the HemoScreen Complete Blood Count (CBC) analyzer from its existing strategic investor.

This recent investment round will be used to establish PixCell’s European presence and expand its ongoing clinical efforts to introduce the HemoScreen technology to the market. HemoScreen CBC analyzer brings the laboratory to physicians' offices, to patient’s homes, isolated communities, ambulances and even to field units. Requiring only a minute blood sample and zero maintenance, it is also ideal for newborns hematology assessment.

PixCell's Viscoelastic Focusing and automated sample preparation proprietary technology, presents a breakthrough in live cell diagnostics, utilizing lab accurate and robust testers yet small sized, simple to operate and inexpensive.

“We are thrilled with our investors’ commitment to make HemoScreen POC technology available and accessible”, said PixCell Medical CEO Dr. Avishay Bransky. “PixCell’s goal is to make lab restricted tests more accessible, easy to use and affordable. With this new investment, PixCell is poised to expand its clinical efforts and further demonstrate how the HemoScreen technology can support diagnostics and treatment selection at the point of care.”

PixCell’s HemoScreen is a miniature, portable Point of Care Complete Blood Count (CBC) tester that employs disposable self-contained cartridges. The HemoScreen provides 20 standard CBC parameters including: RBC indices, WBC count, Hemoglobin, WBC 5-diff and platelets parameters. Tests results are obtained within 5 minutes using only 20µl of capillary/venous blood.

PixCell Medical plans to start a multi-center pilot study in Europe and Israel to evaluate the safety and performance of the HemoScreen system. Prior pre-clinical studies have successfully demonstrated its precision and accuracy in CBC analysis.

The company will be participating at the upcoming Medica trade fair with a hands-on HemoScreen Technology demonstration in Hall 16 Stand G40. Medica will be held November 20-23, 2013 in Dusseldorf, Germany.

About PixCell Medical Technologies Ltd.
PixCell Medical Technologies is an innovative privately held company developing Cell-Based Diagnostics for the Point of Care (POC), based on its patented viscoelastic focusing and microfluidics technology. The core technology is comprised of an Analyzer and a Self-Contained Disposable Cartridge.
• Viscoelastic Focusing – a new physical phenomenon that was recently discovered at the Technion – Israel Institute of Technology and is exclusively licensed to PixCell Medical. Viscoelastic Focusing causes
cells, which are suspended in the patented fluid, to perfectly align i.e. focus and facilitate their optical detection and analysis.

- Disposable Cartridge – PixCell’s patent pending self-contained single-use cartridge enables whole blood sample collection and automated sample preparation in a simple single step.
- Novel Microfluidic Chip – The pure plastic chip is based on a propriety design which facilitates simultaneous multiple analyses on the same sample.
- Image-Based Analysis – advanced machine-learning algorithms are employed in order to analyze the sample instantly.

For more information, please contact:
PixCell Medical Technologies Ltd.
6 Hayezira St., POB 113, Yokneam Ilit 20692, Israel
Tel: +972-4-959-3516 / 7, Fax: +972-4-959-3518
Mail: info(at)pixcell-medical(dot)com
Contact Information
Hanan Ben-Asher
PixCell Medical Technologies Ltd.
http://www.pixcell-medical.com
+972 542355444

Online Web 2.0 Version
You can read the online version of this press release here.